Literature DB >> 16556130

The effect of continuous veno-venous hemofiltration or direct hemoperfusion with polymyxin B-immobilized fiber on neutrophil respiratory oxidative burst in patients with sepsis and septic shock.

Toshio Naka1, Masahiro Shinozaki, Tadao Akizawa, Yukihiro Shima, Hideki Takaesu, Hideki Nasu.   

Abstract

Neutrophil activates and injures tissues and organs during sepsis or septic shock. Blood purification therapies such as continuous veno-venous hemofiltration (CVVH) and direct hemoperfusion with polymyxin-immobilized fiber (PMX-DHP) have been used for the treatment of sepsis and septic shock, however, the effects of such therapies on neutrophil activation have previously been poorly understood. We sought to evaluate neutrophil reactive oxygen species (ROS), especially H2O2 production, in the pathophysiology of sepsis or septic shock and the effect of CVVH or PMX-DHP on neutrophil ROS. Seven critically ill septic patients requiring CVVH (and 12 matched septic patients who did not require CVVH as control) and seven septic shock patients treated with PMX-DHP were studied. We found that patients with sepsis or septic shock had significantly higher levels of neutrophil ROS compared with normal volunteers (183 +/- 42, 292 +/- 90, and 103 +/- 30) (P < 0.05, and < 0.005). Neutrophil ROS did not change over time in patients treated either with CVVH or without CVVH. In contrast, neutrophil ROS significantly inhibited PMX-DHP treatment in patients with septic shock (pretreatment; 292 +/- 88 vs. post-treatment; 205 +/- 93, P < 0.05). In conclusion, neutrophil ROS was significantly enhanced in the sepsis or septic shock affected patients. CVVH did not affect neutrophil ROS while PMX-DHP significant inhibited neutrophil ROS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16556130     DOI: 10.1111/j.1744-9987.2006.00339.x

Source DB:  PubMed          Journal:  Ther Apher Dial        ISSN: 1744-9979            Impact factor:   1.762


  5 in total

1.  Serratia marcescens serralysin induces inflammatory responses through protease-activated receptor 2.

Authors:  Yutaka Kida; Hiroyoshi Inoue; Takashi Shimizu; Koichi Kuwano
Journal:  Infect Immun       Date:  2006-10-16       Impact factor: 3.441

Review 2.  Anti-endotoxin Properties of Polymyxin B-immobilized Fibers.

Authors:  Tohru Tani; Tomoharu Shimizu; Masaji Tani; Hisataka Shoji; Yoshihiro Endo
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

3.  A Case of Polymyxin b-Immobilized Fiber Column Treatment for Rapidly Progressive Interstitial Pneumonia Associated with Clinically Amyopathic Dermatomyositis.

Authors:  Oh Sasaki; Makoto Dohi; Hiroaki Harada; Mitsuru Imamura; Yumi Tsuchida; Kensuke Yamaguchi; Toshihiko Komai; Kazuhiko Yamamoto
Journal:  Case Rep Med       Date:  2013-07-28

4.  Effect of hemoperfusion using polymyxin B-immobilized fibers on acute lung injury in a rat sepsis model.

Authors:  Toshiaki Iba; Isao Nagaoka; Atsushi Yamada; Masataka Nagayama; Takahiro Miki
Journal:  Int J Med Sci       Date:  2014-01-17       Impact factor: 3.738

5.  Successful Recovery from COVID-19-associated Acute Respiratory Failure with Polymyxin B-immobilized Fiber Column-direct Hemoperfusion.

Authors:  Yusaku Kusaba; Shinyu Izumi; Jin Takasaki; Manabu Suzuki; Daisuke Katagiri; Takashi Katsuno; Shuichiro Matsumoto; Keita Sakamoto; Masao Hashimoto; Norio Ohmagari; Harutaka Katano; Tadaki Suzuki; Masayuki Hojo; Haruhito Sugiyama
Journal:  Intern Med       Date:  2020-08-29       Impact factor: 1.271

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.